stockrowAlnylam Pharmaceuticals, Inc.
ALNY Healthcare Biotechnology
Alnylam Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 65.2% from fiscal 2024.
- Revenue
- +16.7%
- EPS
- +747.6%
- Free cash flow
- −4.76%
- Total debt
- −2.66%
Quarter to September 2026, against a year earlier
Follow ALNY
Alert me
Alnylam Pharmaceuticals, Inc. (ALNY) Return on assets
Alnylam Pharmaceuticals, Inc.'s return on assets over the twelve months to 30 September 2026 was 41.3%, up 34.4 percentage points from fiscal 2025 (6.82%). Over the past ten years it has ranged from −44.6% (fiscal 2019) to 6.82% (fiscal 2025) — the current reading is the highest in ten years. That is above the Biotechnology industry median of −45.6% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 6.82% | 13.71 |
| FY2024 | −6.89% | 5.05 |
| FY2023 | −11.9% | 19.53 |
| FY2022 | −31.5% | (7.28) |
| FY2021 | −24.2% | 5.39 |
| FY2020 | −29.6% | 15.06 |
| FY2019 | −44.6% | (1.97) |
| FY2018 | −42.7% | (12.53) |
| FY2017 | −30.1% | 0.82 |
| FY2016 | −31.0% | (7.44) |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| ASND Ascendis Pharma A/S compare | 44.3% |
| ALNY Alnylam Pharmaceuticals, Inc. | 41.3% |
| EXEL Exelixis, Inc. compare | 33.2% |
| INCY Incyte Corporation compare | 5.92% |
| JAZZ Jazz Pharmaceuticals PLC compare | 1.76% |
| ROIV Roivant Sciences Ltd. compare | −5.15% |
| BNTX BioNTech SE Sponsored ADR compare | −7.22% |
| INSM Insmed, Inc. compare | −26.4% |
| BBIO BridgeBio Pharma, Inc. compare | −37.5% |
| Biotechnology industry median | −45.6% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on ALNY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement